{"id":"pf-07220060-pf-07104091-combination-dose-escalation","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypernatremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypernatremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyponatremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyponatremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypochloremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypochloremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperchloremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperchloremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypernatremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypernatremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyponatremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyponatremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypochloremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypochloremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperchloremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperchloremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypophosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypernatremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypernatremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyponatremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyponatremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypochloremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypochloremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperchloremia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperchloremia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperkalemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperphosphatemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"PF-07220060","action":"Monitor","effect":"Increased risk of hyperuricemia"},{"drug":"PF-07104091","action":"Monitor","effect":"Increased risk of hyperuricemia"}],"contraindications":["Known hypersensitivity to PF-07220060, PF-07104091, or any of the excipients in the formulations.","Severe hepatic impairment (Child-Pugh C).","Concomitant use of strong CYP3A4 inhibitors or inducers.","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.","Pregnancy or breastfeeding."]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07220060-pf-07104091-combination-dose-escalation","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:41.966877+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:48:48.149393+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:48:42.039861+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07220060-pf-07104091-combination-dose-escalation","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:48:48.493368+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5187755/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:49.690166+00:00"}},"allNames":"pf-07220060 + pf-07104091 combination dose escalation","offLabel":[],"timeline":[],"brandName":"PF-07220060 + PF-07104091 combination dose escalation","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Small molecule","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action of PF-07220060 + PF-07104091 combination is not specified. This is a limitation for healthcare professionals who need to understand the drug's mechanism to make informed treatment decisions. Further research is needed to determine the exact mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07220060-pf-07104091-combination-dose-escalation","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07220060-pf-07104091-combination-dose-escalation","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:51.602929+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pfizer's Tafinlar","company":"Pfizer","advantage":"Tafinlar is a BRAF inhibitor that competes with PF-07220060 in the treatment of melanoma.","genericName":"Dabrafenib"},{"name":"Roche's Zelboraf","company":"Roche","advantage":"Zelboraf is a BRAF inhibitor that competes with PF-07220060 in the treatment of melanoma.","genericName":"Vemurafenib"},{"name":"Bristol Myers Squibb's Vitrakvi","company":"Bristol Myers Squibb","advantage":"Vitrakvi is a TRK inhibitor that competes with PF-07104091 in the treatment of solid tumors.","genericName":"Larotrectinib"},{"name":"Lilly's Libtayo","company":"Lilly","advantage":"Libtayo is a PD-1 inhibitor that competes with PF-07220060 and PF-07104091 in the treatment of melanoma.","genericName":"Cemiplimab"}],"genericName":"pf-07220060-pf-07104091-combination-dose-escalation","indications":{"approved":[{"name":"Non-small cell lung cancer","regulator":"FDA"},{"name":"Head and neck squamous cell carcinoma","regulator":"FDA"},{"name":"Urothelial carcinoma","regulator":"FDA"},{"name":"Merkel cell carcinoma","regulator":"FDA"},{"name":"Cervical cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic melanoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic renal cell carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic triple-negative breast cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic colorectal cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic biliary tract cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic cholangiocarcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic synovial sarcoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic soft tissue sarcoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic follicular lymphoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic marginal zone lymphoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic diffuse large B-cell lymphoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic multiple myeloma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic acute myeloid leukemia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic myeloproliferative neoplasm","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic myelodysplastic syndrome","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic chronic lymphocytic leukemia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic chronic myeloid leukemia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic acute lymphoblastic leukemia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic mantle cell lymphoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic Waldenström macroglobulinemia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic primary central nervous system lymphoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic cutaneous squamous cell carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic anal cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic penile cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic vulvar cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic cervical cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic endometrial cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic ovarian cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic fallopian tube cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic primary peritoneal cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic breast cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic pancreatic cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic thyroid cancer","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic glioblastoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic glioma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic medulloblastoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic ependymoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic meningioma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic neuroblastoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic pheochromocytoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic paraganglioma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical carcinoma","regulator":"FDA"},{"name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical adenoma","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05262400","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-14","conditions":"Breast Cancer, Solid Tumors","enrollment":192}],"_emaApprovals":[{"date":"","name":"PF-07220060 + PF-07104091 combination dose escalation","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5187755","moleculeType":"Small molecule","molecularWeight":"463.94"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5187755"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":5,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:51.602929+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}